

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 17/08, A61K 37/02	A1	(11) International Publication Number: WO 93/12145 (43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/US92/11238 (22) International Filing Date: 18 December 1992 (18.12.92) (30) Priority data: 07/811,050 19 December 1991 (19.12.91) US (71) Applicant: BAYLOR COLLEGE OF MEDICINE [US/ US]; One Baylor Plaza, Houston, TX 77030 (US). (72) Inventors: ATASSI, M., Zouhair ; 11743 Cawdor Way, Houston, TX 77024 (US). ASHIZAWA, Tetsou ; 3435 Westheimer Road, #301, Houston, TX 77027 (US). (74) Agent: McDANIEL, C., Steven; Conley, Rose & Tayon, P.O. Box 3267, Houston, TX 77253-3267 (US).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, PT, RO, RU, SD, SE, UA, Eu- ropean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: PVA OR PEG CONJUGATES OF PEPTIDES FOR EPITOPE-SPECIFIC IMMUNOSUPPRESSION (57) Abstract The invention relates to a procedure for synthesis of well-defined conjugates of peptides to the tolerogenic polymer monomethoxypolyethylene glycol (mPEG) or polyvinyl alcohol (PVA). This method results in the preparation of conjugates in which one molecule of tolerogenic polymer is specifically coupled to one or the other or both of the termini of an otherwise unaltered peptide molecule. A synthetic peptide synthesized using this method and corresponding to a myasthenogenic region of an acetylcholine receptor was conjugated to monomethoxypolyethylene glycol. Injection of animals with the mPEG-conjugate and subsequent immunization with whole receptor suppressed the development of experimental autoimmune myasthenia gravis (EAMG) by electrophysiological criteria. Specifically conjugated, tolerogenic peptides are also disclosed for diseases as diverse as ragweed pollen allergy and Grave's disease.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

10

PVA OR PEG CONJUGATES OF PEPTIDES
FOR EPITOPE-SPECIFIC IMMUNOSUPPRESSION

15

This invention was made, at least in part, with government support under Grant No. NS26280 awarded by the National Institutes of Health. The government may have certain rights in the invention.

20

The invention relates, in one aspect, to a procedure for synthesis of well-defined conjugates of peptides covalently bonded to a tolerogenic polymer such as monomethoxypolyethylene glycol (mPEG) or polyvinyl alcohol (PVA). The first step in said synthesis involves succinylation of free-hydroxyl groups on the tolerogenic polymer by reaction with succinic anhydride. The polymer is then coupled to one or the other terminus, for instance via the carboxyl of a succinyl group to the α -NH₂ of a peptide. This is achieved while maintaining intact all the side-chain protecting groups on the peptide. The MPEG or PVA-peptide conjugate are cleaved from a synthetic resin and purified. This method results in the preparation of conjugates in which one molecule of tolerogenic polymer is specifically coupled to one or the other or both of the termini of an otherwise unaltered peptide molecule.

In order to test the ability of such tolerogenic peptides to suppress antibody responses in an autoimmune disease, a synthetic peptide, α 125-148, corresponding to a myasthenogenic region of *Torpedo californica* acetylcholine receptor (AChR) was conjugated to monomethoxypolyethylene glycol (MPEG). Injection of mice with the MPEG-(α 125-148) conjugate and subsequent immunization with whole *Torpedo* AChR suppressed the development of experimental autoimmune myasthenia gravis (EAMG) by electrophysiological criteria. In anti-AChR antisera from these animals, the antibody response against the unconjugated peptide α 125-148 was decreased while the antibody responses against whole AChR and other epitopes were not altered. There were no detectable changes in T cell proliferation responses to peptide α 125-148 or to whole AChR in these animals. Prior injections with a "nonsense" peptide MPEG conjugate had no effect on responses to the subsequent immunization with whole *Torpedo* AChR. The results indicate that the MPEG-(α 125-148) conjugate has epitope-specific tolerogenicity for antibody responses in EAMG, and that the region α 125-148 plays an important pathophysiological role in EAMG. These studies strongly indicate that other epitope-directed tolerogenic conjugates will be useful for future immunotherapies of human myasthenia gravis.

Tolerogenic peptides are also disclosed for diseases as diverse as ragweed pollen allergy and Grave's disease. The strategy of specific suppression of the antibody response to a pre-determined epitope using a synthetic MPEG-peptide conjugate will be useful in manipulation and suppression of unwanted immune responses such as autoimmunity and allergy.

Some of the earliest methods combining the use of amino acid synthesis with polymers such as polyethylene

glycol (PEG) were as a resin for the synthesis of peptides. These methods relate generally to attachment of PEG at the carboxy terminus of the growing peptide chain. Typically, the resulting synthetic peptide is ultimately cleaved from the PEG resin and purified. For instance, Anzinger and Mutter (1982), relates to modified PEG moieties capable of binding both C- and N-termini of synthetic peptides for purposes as a soluble carrier and as a solubilizing protecting group in peptide syntheses.

10

Alternatively, tolerogenic polymers have been used to derivatize proteins and peptides in a permanent, covalent fashion. Prior research has shown that mPEG-protein conjugates may be constructed by non-selective coupling of the polymer to proteins, usually via the ϵ -amino groups of lysine residues on the surfaces of such proteins. Such substitutions result in multiple derivatives.

15
20

Previous studies, for instance, have shown that conjugation of polyethylene glycol, monomethoxypolyethylene glycol (MPEG) or polyvinyl alcohol (PVA) with various protein antigens causes a loss of most of the antigenicity of the native antigens (Abuchowski et al., 1977; Lee and Sehon 1977, 1978a; King et al., 1977, 1979; Davis et al., 1980; Sehon and Lang, 1986). It has also been demonstrated that prior injection of animals with antigen-mPEG conjugates leads to the development of tolerance to subsequent immunization with the native antigen (Lee and Sehon 1977, 1978b; King et al., 1979).

25
30

mPEG-derivatization has been used to produce whole-protein and protein fraction conjugates. Abuchowski et al. (1977) relates, for instance to the derivatization of bovine serum albumin with mPEG causing this molecule to

35

become essentially non-immunogenic. Lee and Sehon (1977) similarly converted ovalbumin and mixtures of non-dialyzable allergenic constituents of the aqueous extract of ragweed pollen. King et al. (1979) relates to the comparative study of different tolerogenic polymers indiscriminately conjugated with ragweed antigen E. Nishimura, et al. (1983), relates to the use of an indiscriminately PEG-derivatized snake venom with a molecular weight of 36,000. British Patent 1 469 472 appears to relate to the desire to provide polypeptides such as insulin a longer residence time in the circulatory system and a lessened allergic reaction in the same by apparently indiscriminate conjugation of such polypeptides to PEG.

In certain cases, the indiscriminate conjugation of polymer to protein has been controlled to a limited extent. For instance, European Patent Application 0 335 423 relates to the hG-CSF polypeptide derivatized with a PEG moiety. The derivatization appears to be indiscriminate even though the disclosure does provide for as few as a single PEG molecule per molecule of hG-CSF by controlling the stoichiometric ratios of the polymer to protein. Kita, et al. (1990), relates to the selective modification of one of three (including the N-terminal) residues within human interferon in order to obtain active interferon from recombinant bacteria. The PEG modification was seen to increase the serum half-life of the interferon without substantial decrease in its biological efficacy.

Tolerogenic polymers have also been used to derivatize certain peptides. In the past, modifying peptides with PEG generally required use of methods for activation including: (1) activation with triazine derivatives of PEG; (2) activation of PEG using the

active ester method with N-hydroxysuccinimide; (3)
activation of PEG with carbonyldiimidazole; (4)
activation of PEG with aldehydes; and so on. These
modification methods involve modifying the amino groups
5 at the N-terminal or in the side chain of the lysine
residues of the peptides. For instance, Becker and Bayer
(1979), relates to synthetic peptides with PEG conjugated
to NH_2 groups which are available for coupling. In
certain cases, where the only reactive NH_2 group in the
10 peptide is the $\alpha\text{-NH}_2$, the PEG molecule was conjugated to
the N-terminus of the peptide. Such methodology,
however, relied on the fact that no other reactive amine
groups existed in the peptide to be derivatized.

15 In some instances, peptides have been derivatized
using distinct chemical moieties apart from the N-
terminus amino group. Ueyama, et al. (1985), relates to
the conjugation of PEG to cysteine-containing peptides
through the carboxy groups in said cysteines. European
20 Patent Applications 0 340 741 and 0 400 486 relate to PEG
derivatives for use as a peptide (particularly protein)-
modifying reagent in peptides having guanidino groups.
PCT International Application, Pub. No. 90/12874, relates
to the modification of polypeptides such as IL, G-CSF or
25 EPO by non-N-terminal conjugation of PEG to cysteine
residues in such polypeptides. Sartore, et al. (1991),
relates to a method of producing a reagent comprising
mPEG attached to an amino acid or a peptide, the amino
acid or peptide functioning as a traceable spacer arm
30 between the reagent and a derivatizable polypeptide in
order to change its immunological properties. The
attachment of the mPEG polymer to the peptide was at the
carboxy terminus leaving, apparently, a free reactive
amine functional group at the other terminus.

It is known, however, that heterogenous mixtures of "PEGylated" polypeptides and peptides are unsuited for pharmacological purposes (see e.g., PCT International Application, Pub. No. 90/12874). Indiscriminately conjugated proteins and peptides will, almost invariably, be expected to contain a mixture of molecular species or derivatives.

The use of tolerogenic antigens, alloantigens and allergens has received recent interest from the medical community for the treatment of autoimmune type disease. Typically, as noted above, the methods of the prior art utilize randomly derivatized whole antigen. Certain models of these diseases are known, however, which may serve as a testing ground for new approaches.

For instance, animals immunized with acetylcholine receptors (AChRs) in the presence of complete Freund's adjuvant produce autoantibodies against AChRs and develop a neuromuscular disease similar to human myasthenia gravis. In this experimental animal disease, called experimental autoimmune myasthenia gravis (EAMG), the majority of the autoantibodies is directed against the main extracellular part of the α subunit of AChR. The mapping of the complete antibody recognition profile, using overlapping synthetic peptides representing the entire extracellular part of the α subunit of *Torpedo californica* AChR, demonstrated that the peptide α 125-138 contains a major antigenic site (Mulac-Jericevic et al., 1987). This epitope is located within the sequence α 125-148 which is a potent region for induction of EAMG (Lennon et al., 1985) and contains the acetylcholine binding site (McCormick and Atassi 1984).

Other autoimmune diseases and other undesirable immune responses such as allergic responses have been

investigated sufficiently well to identify similar specific epitopes which may be the principal causative agent in the disease. Thus, for instance, ragweed pollen allergy is a condition resulting from IgE responses to
5 ragweed allergens such as antigen E, antigen K and Ra3. Thus, it is known from the work of the present inventors that one can map the IgG and IgE antibody and the T-cell epitopes of Ra3 (Atassi and Atassi, 1985, 1986; Kurasaki et al. 1986). Animal models (rat) exist which are used
10 to study the allergic responses.

Similarly, Grave's disease is an autoimmune disease caused by antibody and T-cell responses to epitopes on thyroid-stimulating receptor (TSHR). Recently, the
15 hormone-binding regions on TSHR were localized (Atassi, et al. 1991). As is known due to recent press coverage, both human (President and Mrs. George Bush) and animal (the family pet dog of the President and First Lady) forms of this disease are known.

20 Where mixtures of indiscriminately derivatized peptides such as the specific epitopes described above are used as tolerogens, problems associated with reproducibility and efficacy are common. In particular,
25 in cases where autoimmune disease are the result of limited specific epitopes being the target of the autoimmune antibodies, tolerogenic mixtures are not desirable. What are needed are specifically-derivatized, epitope-specific conjugated peptides.

30 The present invention overcomes at least some of the problems existing in prior art approaches to the construction of reagents for the treatment of autoimmune diseases. In one aspect, the invention broadly discloses
35 a synthetic method for construction of specifically-modified peptides covalently attached to a polymer which

renders the synthetic peptide tolerogenic. In another aspect, the invention broadly discloses the use of these specifically-modified synthetic peptides in the treatment of diseases of autoimmunity and other unwanted responses such as allergic reactions and graft rejections. In yet another aspect, the invention provides for the reagents designed to immunosuppress undesirable immune responses. The invention also provides a method of testing such reagents for efficacy as immunosuppressants.

More specifically, a method of producing reagents useful in the treatment of autoimmune diseases is disclosed herein. In certain preferred aspects, the method for producing such reagents entails producing a peptide covalently linked via its carboxy-terminal amino acid to a synthetic resin. It will be understood well by those of skill in the art, however, that due to its ease, coupling of the carboxy terminus to the synthetic resin is only one manner in which to provide a single free amino terminus for subsequent derivatization. However, the same skilled artisan will also realize that it is possible to use alternative protocols to specifically block the amino terminus and to derivatize the carboxy terminus of such a peptide. Therefore, while the preferred technique will involve a carboxy terminus attached to a synthetic resin and a free amino terminus, derivatization of either or both termini is anticipated by the inventors to give equally efficient tolerogenic peptides.

Any of the synthetic resins known to those of skill in the art will be amenable to the methodology. For instance, one may use synthetic methods based on either t-butyloxycarbonyl (t-Boc) derivatized amino acids synthesized on a phenylacetamidomethyl (PAM) resin or by 9-fluorenmethylcarbonyl (Fmoc) derivatized amino acids on

a benzyloxybenzyl alcohol resin (McCormick and Atassi 1984; Mulac-Jericevic and Atassi, 1987; Atassi et al., 1991).

5 The peptides of the invention will typically be protected from inadvertent coupling along the side chains by the presence of side chain-protected amino acids in the peptide. It will be well understood by those of skill in the art that such side chain protecting groups
10 can vary depending upon the nature of the synthetic procedure.

 In the preferred embodiment, the peptide may be synthesized beginning with any sized initial peptide
15 fragment attached by its carboxy terminus to the resin. Thus, it will be understood by those of skill in the art that one may obtain presynthesized and derivatized peptides of variable lengths. Alternatively, one may
20 obtain from any number of commercial sources synthetic resins which have one or more derivatized amino acids coupled to the resin by its carboxy terminus. The
invention, therefore, is not limited to the use of wholly synthetic peptides and may include peptide fragments
25 derived from native antigens themselves or from antigens obtained using recombinant DNA technology so long as these peptides may be protected along their side chains and covalently bound to a resin at their carboxy or amino terminus.

30 The peptides produced by the methods of the invention will typically correspond to an epitope which is suspected of inducing an autoimmune response or other undesired responses such as allergic conditions or graft
rejections. Such an epitope may be suspected for any
35 number of reasons. There may be empirical data which indicate a specific and relatively restricted epitope as

a linear sequence found as an identical sequence in the native antigen known to cause the immune response of the disease. Alternatively, such an epitope may be a non-linear sequence corresponding to an antigenic region of a native antigen but which linear sequence does not exist as such in the native antigen.

Moreover, the peptides produced by the invention may be suspected as epitopes due to a regional localization to a region known to contain the minimally-sized epitope inducing the maximal antigenic response in the immune disease. For instance, it is known by those of skill in the art that many cell membrane-associated antigens chiefly present the extracellular portions of the polypeptide as potential epitopes. Thus, the epitope suspected of inducing the immune response may only be suspected as a battery of potential epitopes which are typically presented in the physiological state. In some cases, therefore, one may wish to test a battery of overlapping peptides representing sequential segments of the exposed extracellular regions of a given native antigen.

The peptide so selected and/or synthesized is attached to a resin by one of its termini, preferably by its carboxy-terminus, and is then derivatized at its other, preferably amino, terminal amino acid with a tolerogenic polymer. Since all side chains will still be protected as they were during the synthetic procedure, and since one terminus is likewise protected by coupling to the resin, the only reactive group will occur at the other terminus, preferably at the growing N-terminal amino acid as the α -NH₂ of that terminal residue. It is to this terminus that the tolerogenic polymer is attached.

The methods of the invention complete the synthesis of the terminally protected, tolerogenic peptides by deprotecting the side chain-protected amino acids comprising the peptide. Depending on the nature of the synthetic chemistry used to construct the peptide, 5 deprotection will be achieved variously by methods known well to those of skill in the art. Similarly, depending upon the resin used to initiate synthesis, cleaving the peptide from the resin will take various forms. 10 Purification of the peptide will also take various forms depending upon the nature of the resulting peptide. In some cases, more hydrophilic peptides may be amenable to purification schemes depending upon the solubility of the peptide in water based solvents. More hydrophobic 15 peptides may require organic solvents and purification schemes in which the peptides will be most soluble.

Even though methods of the invention relate to any epitope-specific tolerogenic peptide used to construct 20 reagents capable of treating immune diseases, the invention relates more specifically to certain characterized peptide reagents. Thus, the invention discloses the specific construction of any of the peptides shown in Sequence ID Nos. 1-7. Certain of these 25 specific peptide reagents relate to specific immune diseases such as myasthenia gravis, ragweed pollen allergy, and Grave's disease. Moreover, the methods of the invention relate to specific native polypeptides such as a subunit of an acetylcholine receptor, ragweed pollen 30 antigen Ra3, or a polypeptide subunit of the thyroid-stimulating hormone receptor responsible for Grave's disease.

It is preferred that the peptide reagent designed 35 will be directly or indirectly responsible for the major immune response as the principal causative agent of

symptoms of the immune disease. However, there may be instances where peptides corresponding to regions of the native antigen responsible for lesser immune responses will be desired. In particular, combinations of
5 reagents, each of which accounts in part for the immune response, may be preferred in certain instances.

The methods of the invention require the covalent coupling of a tolerogenic polymer to the peptide
10 reagents. Such tolerogenic polymers are known well to those of skill in the art. For instance, such a polymer may be polyethylene glycol or a polyethylene glycol derivative. In a preferred embodiment of the invention, the monomethoxy derivative of polyethylene glycol will be
15 used. Alternatively, polyvinyl alcohol or a derivative of polyvinyl alcohol may be used.

In any instance, the basic polymer selected will be treated in a manner as to make the polymer amenable to a
20 coupling reaction. In a preferred embodiment, the method used to derivatize the polymer will involve succinylation of the polymer so as to derivatize the hydroxyl groups of the polymer and to generate any number of reactive carboxyl groups. Complete derivatization is monitored as
25 is availability of the reactive carboxy groups on the surface of the modified polymer.

In another principal aspect of the invention, a method of treating an autoimmune disease is disclosed.
30 The method consists of first producing a tolerogenic polymer-derivatized peptide as described above. The peptide reagent so produced will typically correspond to an epitope which is suspected of inducing an autoimmune response of the disease. After the peptide is so
35 produced, the method treats a patient with the peptide. The patient may be one who has the disease.

Alternatively, the patient may be one who is likely to develop the autoimmune disease. For instance, certain autoimmune diseases have long non-symptomatic episodes in which major immune responses are not present. In the
5 autoimmune disease myasthenia gravis, patients typically experience sometimes very lengthy non-symptomatic periods followed by periods of almost complete debilitation due to the ongoing immune response. The patient is thus treated at an optimal time with tolerogenic peptide,
10 preferably prior to onset of a major autoimmune response to the natural antigen from which the epitope was designed.

Reagents useful in the treatment of an autoimmune
15 disease are also disclosed in the present invention. Generally, such a reagent will be a peptide corresponding to an epitope which is suspected of inducing an autoimmune response which peptide is derivatized at an N-terminal amino acid of the peptide with a tolerogenic
20 polymer.

More specifically, the reagent will be one of the group of peptides disclosed in Sequence ID Nos. 1-7. It will be recognized, however, by those of skill in the art
25 that the reagent peptides may contain functionally equivalent amino acid substitutions. The importance of the hydropathic index of amino acids in conferring biological function on a protein has been discussed generally by Kyte and Doolittle (1982). It has been
30 found by these researchers and others that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain similar if not identical biological activity. As displayed in Table I below, amino acids are assigned a
35 hydropathic index on the basis of their hydrophobicity and charge characteristics. It is believed that the

relative hydrophobic character of the amino acid determines the secondary structure of the resultant protein, which in turn defines the interaction of the protein with the substrate molecule. Similarly, in peptides whose secondary structure is not a principal aspect of the interaction of the peptide, position within the peptide and the characteristic of the amino acid residue determine the interactions the peptide has in a biological system. It is proposed that biological functional equivalence may typically be maintained where amino acids having no more than a ± 1 to 2 difference in the index value, and more preferably within a ± 1 difference, are exchanged.

TABLE I

	<u>AMINO ACID</u>	<u>HYDROPATHIC INDEX</u>
	Isoleucine	4.5
	Valine	4.2
5	Leucine	3.8
	Phenylalanine	2.8
	Cysteine/Cystine	2.5
	Methionine	1.9
	Alanine	1.8
10	Glycine	-0.4
	Threonine	-0.7
	Tryptophan	-0.9
	Serine	-0.8
	Tyrosine	-1.3
15	Proline	-1.6
	Histidine	-3.2
	Glutamic Acid	-3.5
	Glutamine	-3.5
	Aspartic Acid	-3.5
20	Asparagine	-3.5
	Lysine	-3.9
	Arginine	-4.5

Thus, for example, isoleucine, which has a
hydropathic index of +4.5, can be substituted for valine

SUBSTITUTE SHEET

(+ 4.2) or leucine (+ 3.8), and still obtain a protein having similar biologic activity. Alternatively, at the other end of the scale, lysine (-3.9) can be substituted for arginine (-4.5), and so on.

5

Accordingly, these amino acid substitutions are generally based on the relative similarity of R-group substituents, for example, in terms of size, electrophilic character, charge, and the like. In general, although these are not the only such substitutions, the preferred substitutions which take various of the foregoing characteristics into consideration include the following:

15

TABLE II

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>
	Ala	gly; ser
20	Arg	lys
	Asn	gln; his
	Asp	glu
	Cys	ser
	Gln	asn
25	Glu	asp
	Gly	ala
	His	asn; gln
	Ile	leu; val
	Leu	ile; val
30	Lys	arg; gln; glu
	Met	met; leu; tyr
	Ser	thr
	Thr	ser
	Trp	tyr
35	Tyr	trp; phe
	Val	ile; leu

More particularly, the invention relates to a method of producing reagents useful in the treatment of myasthenia gravis. In such a method, a peptide is synthesized corresponding to the peptide shown in Sequence ID No. 5. This peptide is covalently linked during and after synthesis to a carboxy-terminal amino acid of the peptide to a resin and possesses side chain-protected amino acids. As is described in more detail below, this peptide corresponds to an epitope which is suspected of inducing a myasthenia gravis autoimmune response. The peptide is then derivatized at an N-terminal amino acid of said peptide with mPEG. Following derivatization with the tolerogenic polymer, the reagent is deprotected along its the side chain-protected amino acids, cleaved from the resin, and purified. Even though such a specific reagent is disclosed, it will be understood that other myasthenogenic peptides will be amenable to the general methods of the invention in order to produce suitable reagents for treatment of the disease alone or in combination with other drugs and treatments.

A similar method is disclosed relating to production of reagents useful in the treatment of ragweed allergy. In the case of the specific ragweed peptide disclosed herein, the peptide will correspond to the peptides shown in Sequence ID Nos. 1-4. Similarly, a method of producing reagents useful in the treatment of Grave's disease are disclosed herein. Reagents produced by any of the methods of the invention as they relate to Grave's disease are also disclosed (See, Atassi et al. *Proc. Ntl. Acad. Sci USA* 88:3613-3617 [1991], specifically incorporated by reference herein).

As regards specific methods of treating specific immune diseases, the invention discloses methods for treating myasthenia gravis, ragweed allergy, and Grave's

disease. In certain preferred embodiments, these methods will more particularly utilize an mPEG-derivatized peptide corresponding to those peptides identified in Sequence ID Nos. 1-7.

5

In another major aspect of the invention, methods of screening reagents potentially useful in the treatment of autoimmune diseases is disclosed. In a general application of this method, one produces a peptide covalently linked via one of its terminal ends, such as the N-terminal amino acid, of the peptide to a resin such as those disclosed below, protecting the amino acid residues accordingly with side chain-protecting groups. The candidate peptide will typically correspond to an epitope or an amino acid sequence from a region believed to contain such an epitope, which is suspected of inducing an autoimmune response. The candidate reagent will be completed by derivatizing the N-terminal α -NH₂ (or the C-terminal carboxyl) of the peptide with a tolerogenic polymer, deprotecting the side chain-protected amino acids comprising the peptide, cleaving the peptide from the resin, and purifying the peptide.

As a next step in the screening method, a test subject having, or likely to develop, the immune (such as an autoimmune) disease or an experimental model of the immune disease is treated with the peptide reagent. The treatment will preferably occur prior to onset of an immune response to an autoantigen (or allergen) or transplantation antigen comprising the epitope. Finally, the test subject will be evaluated for alleviation of symptoms related to said immune response.

It will be understood by those of skill in the art that the method of screening generally outlined above will typically be applied where the peptide under

investigation is one of a battery of peptides whose sequences are derived in some manner from the native protein suspected of causing the immune response.

Methods of treatment of the test subject may vary according to the nature of the reagent or the strictures of the testing protocols, but typically will involve the injection of the peptide reagent into the test subject at selected intervals and without an adjuvant.

10 A method of screening reagents potentially useful in the treatment of myasthenia gravis, is described, for instance, which involves producing peptides using the methods described herein based upon the extracellularly accessible regions of certain polypeptide subunits of the
15 acetylcholine receptor. The test subject is then treated with the tolerogen-peptide conjugate. The test subject may be a human test subject having, or likely to develop, myasthenia gravis. Alternatively, and in a preferred embodiment where experimental drugs are first screened,
20 the test subject may be a non-human animal such as a mouse in which experimental autoimmune myasthenia gravis has been induced using injections of the native antigen, acetylcholine receptor derived from the *Torpedo*. As described previously, one wishing to use such a screening
25 method will typically time the treatments of the test subject with the peptide reagent prior to onset of an autoimmune response to an acetylcholine receptor polypeptide. The test subject following treatment will be evaluated for alleviation of symptoms related to
30 myasthenia gravis or an experimentally induced model thereof. Where possible, evaluation of the test subject for alleviation of symptoms further comprises evaluating the test subject using electrophysiological criteria.

35 Fig. 1. Covalent structure of the synthetic peptides used in the present work for coupling to mPEG

and to PVA. Peptide 1 was synthesized on a PAM-resin by t-Boc amino acids as described earlier (from McCormick and Atassi, 1984). Peptides 2-6 were synthesized on a benzyloxybenzyl alcohol resin by Fmoc amino acids.

5

Fig. 2. Scheme for synthesis of mPEG-peptide and PVA-peptide conjugates. In step A, the aliphatic hydroxyl groups on mPEG and PVA are reacted with succinic anhydride. In step B, the synthetic peptide, while still on the resin with all the side-chain protecting groups intact, is deprotected at the α -NH₂ group only (compound 2) and then coupled through this now free amino group to the carboxyl group of compound 1 using a carbodiimide and an excess of compound 1. Complete blocking of the amino group is monitored and recoupling is performed if necessary. When free amino groups are no longer detectable, the peptide is cleaved from the resin. This scheme is a general procedure for the synthesis of mPEG-peptide and PVA-peptide conjugates (compound 3). The peptide conjugate is then lyophilized and subjected to purification.

Fig. 3. An example of elution profiles of (1) the parent unconjugated peptide (peptide 5, Fig. 1) and (2) an mPEG-peptide conjugate in HPLC on a size exclusion column (Waters Protein Pak 60, 0.7 x 30 cm). The column was eluted with 0.2 M ammonium bicarbonate containing 20% acetonitrile at 0.70 ml/min.

Fig. 4. Elution profiles of: (1) peptide α 125-148, and (2) mPEG-(α 125-148) conjugate in HPLC on a size exclusion column (Waters protein pak 60, 0.7 x 30 cm). The column was eluted with 0.2 M ammonium bicarbonate containing 20% acetonitrile at 0.70 ml/min.

35

Fig. 5. Protocol for the intraperitoneal injections of C57/BL6 mice with mPEG-peptide conjugates (or the unconjugated peptide) and subsequent immunizations with whole Torpedo AChR.

5

Fig. 6. An example of electrophysiological findings from a normal mouse and an EAMG-positive mouse. (A) EMG response of a normal mouse to a train of 3 Hz repetitive stimulation. (B1) a typical decremental response (-33%)
10 in an EAMG-positive mouse. (B2) the decremental amplitude in B1 was substantially restored towards normal (-13%), 3 minutes after an intraperitoneal injection of 250 μ g edrophonium chloride.

15 Fig. 7. Effects of prior administration of mPEG-(α 125-148) on the development of electrophysiological EAMG after immunization with AChR (see Fig. 4). Note that in Group 1 mice, both the mean amplitude change and the proportion of mice showing greater than 10% decrement
20 were smaller than Groups 2 or 3 ($p < 0.05$), but greater than Group 4, mice ($p < 0.05$), suggesting that the mPEG-(α 125-148) conjugate suppresses development of electrophysiological EAMG but the suppression was incomplete.

25

Fig. 8. Effects of pre-administration of mPEG-(α 125-148) on the antibody response to immunization with AChR. The anti-AChR antisera from the three groups of mice (Groups 1-3) were studied for antibody binding
30 to: (A) peptide α 125-148; (B), whole AChR; (C) peptide α 45-60 and (D) peptide α 182-198 as described in the text. In A, Group 1 mice showed significant suppression of the antibody population that binds with peptide α 125-148 (mean net cpm \pm standard deviation = 1414 ± 1801 compared
35 to the mice in Group 2 (3334 ± 2318 , $p < 0.005$) and Group 3 (3626 ± 2214 , $p < 0.005$). Antibodies against whole receptor

(shown in B; $P > 0.5$), peptide $\alpha 45-60$ (shown in C; $P > 0.1-0.5$) and peptide $\alpha 182-198$ (shown in D; $P > 0.1-0.5$) suffered no significant suppression in Group 1 compared to the control groups.

5

Fig. 9. Binding to peptide $\alpha 125-148$ of anti-AChR antibodies in pooled antisera from each group of mice (see Fig. 6). Antisera were studied at various dilutions as shown. The pooled antisera from Group 1 mice (\diamond) showed considerably lower antibody binding to the peptide than antibodies from Groups 2 (\bullet), 3 (\blacksquare), and 5 (\blacktriangle) (see text).

10

Fig. 10. Effects of pre-administration of mPEG-($\alpha 125-148$) on the T cell proliferative responses after immunization with AChR. The T-cell recognition profiles of EAMG-negative mice (C57/BL6) from Group 1 and EAMG-positive mice from Group 2 were mapped with uniform sized, overlapping synthetic peptides corresponding to the entire extracellular part of the α chain of Torpedo AChR (Mulac-Jericevic et al., 1987a,b) and with peptide $\alpha 125-148$ (loop) (McCormick and Atassi, 1984). In these assays LNC (5×10^5 cells/well) were challenged in vitro with various doses of peptide ($10-40 \mu\text{g/ml}$), AChR ($1.5-6.0 \mu\text{g/ml}$). Nonsense peptide, lysozyme and ovalbumin were used as negative controls and added to the cells in the same dose ranges for peptides and AChR, respectively. Concanavalin A ($1 \mu\text{g/ml}$) was used as a positive control. The results were done in triplicate and repeated twice.

EAMG-positive and EAMG-negative mice were selected on the basis of the EMG test.

20

25

30

In general aspects, certain protocols and procedures will be applicable to the various methods and compositions of matter of the invention. These general techniques are detailed below.

35

Peptide Synthesis and Purification

The peptides used for certain particular examples of the invention are shown in Fig. 1 and correspond to the Sequence ID Nos. 1-6. These peptides, as well as other peptides produced using the methods of the invention, are synthesized either by t-butyloxycarbonyl (t-Boc) on a phenylacetamidomethyl (PAM) resin or by 9-fluorenmethylcarbonyl (Fmoc) amino acids on a benzyloxybenzyl alcohol resin as described elsewhere (McCormick and Atassi 1984; Mulac-Jericevic and Atassi, 1987; Atassi et al., 1991), together with methods for purification and characterization of the peptides.

Succinylation of the hydroxyl groups of mPEG and PVA

To prepare the succinate esters of mPEG and PVA, one gram of mPEG (molecular weight, 5000) or PVA (molecular weight 3,000) is dissolved in 5 ml anhydrous pyridine at 50°C, and to these solutions aliquots of succinic anhydride (0.5 g each) are added as a dry powder at 1-hour intervals. Following the last addition, the reaction mixture is stirred for 2 hours at 50°C, after which it is evaporated to dryness on the flash evaporator. The residue is dissolved in water and evaporated to dryness and this washing with water on the evaporator is repeated several times until the odor of pyridine in the residue is very faint. The residue is dissolved in water (10 ml) and dialyzed, in a 1000-molecular weight cut-off dialysis membrane, against several changes of distilled water and finally freeze-dried (yield 0.92-0.95 g). Complete succinylation of the polymers is confirmed by a negative reaction for hydroxyl and a positive reaction for carboxyl groups.

Determination of hydroxyl and carboxyl groups in the polymers

Determination of hydroxyl groups is carried out by a modification of the procedure described by Siegelman et al. (1962). A solution of test sample (365 μ l containing 2 mg of mPEG, PVA mPEG-Su, PVA-SU, succinic anhydride, and standards containing various amounts of methanol from 0 to 1.5 μ mole in 0.06 M sodium phosphate buffer pH 7.5, containing 0.09 M NaCl, is mixed with 182 μ l of 0.75 M perchloric acid. A blank is prepared which contains the same reagents but without a test sample. After mixing, the tubes are centrifuged (2000 rpm, 20 min.) and 365 μ l aliquots from each tube are transferred to clean test tubes. To each tube is added 40 μ l of 2% KMnO_4 (in water), the solutions are mixed for exactly 1 minute, then 40 μ l of freshly prepared 10% sodium sulfite (in water) is added and the tubes are immediately shaken vigorously. At this point, the solutions should become completely decolorized. To these solutions is added 1.45 ml of chromotropic acid reagent [8 mg of 4,5-dihydroxy-2,7-naphthalene-disulfonic acid disodium salt (Sigma Chemical Co., St. Louis, MO) dissolved in 0.10 ml H_2O and 1.35 ml sulfuric acid solution (Conc. H_2SO_4 /water, 2:1, v/v)]. The tubes are covered and placed in boiling water for 15 min. after which they are cooled to room temperature and the absorbance of the solutions is read at 580 nm against the blank solutions in the reference cell. The hydroxyl group content of a sample is determined based on the methanol standard curve of absorbance versus amount of methanol ($A^{1\text{cm}}_{580}$ for 1 μ mole of $\text{CH}_3\text{OH} = 0.856$).

Carboxyl groups are detected by the method described by Brown (1951). An aliquot of a water solution of the test sample (20 μ l containing 1 mg of mPEG, PVA mPEG-Su or PVA-SU) is applied as a spot on Whatman No. 3MM Chr

paper. The spot is dried with cold air and the paper is then stained by spraying with a solution of 0.04% bromothymol blue in ethanol, preadjusted to pH 8.0 with 0.2 M boric acid. mPEG-Su and PVA-Su give bright yellow spots on a blue background, whereas the spots of mPEG and PVA appear blue.

Coupling of mPEG or PVA succinates to synthetic peptides

A coupling method for the preparation of mPEG-peptide and PVA-peptide conjugates is illustrated in Fig. 2. The synthesis resin (0.1g) carrying the completed synthetic peptide (0.025 m mole), with all the side chain protecting groups intact, is swollen in a synthesis vessel in methylene chloride overnight. The t-Boc protecting group on the α -amino group of the synthetic peptide is removed by treatment with 40% trifluoroacetic acid containing 2% anisole and 2% dimethylformamide (DMF) at room temperature for 30 minutes. For the Fmoc-peptides, the N^α-Fmoc protecting group is removed by 20% piperidine in DMF. For coupling of mPEG-Su, a three-molar excess in 1.5 ml of DMF is reacted with 0.2 ml of 50% dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIPC) in methylene chloride for 20 minutes, filtered to remove dicyclohexyl urea (if DCC is used), then added to the N-terminal-deprotected peptide-resin and allowed to react for 24 hours. For coupling of PVA-Su, larger reaction volumes are needed because of its tendency to gel. Three-molar excess of PVA-Su is dissolved in 8.0 ml of DMF and to this is added 0.20 ml of 50% DCC or DIPC in methylene chloride. Three cycles of recoupling of mPEG-Su or PVA-Su to the peptide-resin are done. The complete blocking of the α -NH₂ is confirmed by a ninhydrin test (Kaiser et al, 1970). After the α -amino group on the peptide is completely blocked, uncoupled mPEG-Su or PVA-Su is washed out of the vessel with methylene chloride and then

methanol. The peptide conjugate is cleaved from the resin by HF (Sakakibara et al, 1967), if a PAM resin and t-Boc amino acids are used, or by treatment (2.5 hr) with 55% trifluoroacetic acid in methylene chloride if a benzyloxybenzyl alcohol resin and Fmoc amino acids are used.

Any residual uncoupled peptide is removed from the conjugate by gel filtration on a Sephadex G-75 fine column (1.5 x 75 cm) in 0.1 M ammonium bicarbonate and by high pressure liquid chromatography (HPLC) on a size exclusion column (Waters protein pack 60, 0.7 x 30 cm) which is eluted with 0.2 M ammonium bicarbonate containing 20% acetonitrile at a flow rate of 0.7 ml/min.

15

Preparation of Torpedo AChR

The purification of Torpedo AChR is carried out as described elsewhere (Froehner, 1979; Mulac-Jericevic and Atassi, 1987). Briefly, the electric organ of Torpedo californica (Pacific Bio-Marine Laboratories, CA) is homogenized and the membrane proteins are extracted in 1% Triton X-100 (Sigma Chemical Company, MO). After centrifugation, the AChR in the supernatant is affinity purified on a cobratoxin Sepharose CL4B column using 1M carbamylcholine in 1% octyl β -D-glucopyranoside (Sigma Chemical Company, MO) for the elution of the AChR. The purified AChR is composed of the expected four subunits (α , β , γ , δ) as demonstrated by SDS-PAGE (Laemmli, 1970).

Synthesis of Myasthenic Peptides and their mPEG conjugates

The structure of peptide α 125-148 (Fig. 1, No. 5) of Torpedo AChR was based on the amino acid sequence of the extracellular part of the receptor (Noda et al., 1982). The peptide was synthesized and purified as described by McCormick and Atassi (1984). Cyclization of the

synthetic peptide α 125-148 was performed under conditions previously described (McCormick and Atassi, 1984). The monomeric form was separated by gel filtration on Sephadex G-25 fine (Pharmacia Fine Chemicals) column in 0.1 M ammonium bicarbonate. After purification, homogeneity of the monomeric peptide was confirmed by high-voltage paper electrophoresis (Atassi and Saplin 1968). The amino acid composition of the peptide was in excellent agreement with that expected from its sequence.

5 0.1 M ammonium bicarbonate. After purification, homogeneity of the monomeric peptide was confirmed by high-voltage paper electrophoresis (Atassi and Saplin 1968). The amino acid composition of the peptide was in excellent agreement with that expected from its sequence.

10 A nonsense peptide, having a structure (HFKSFHSFVSGETVFEVTEAG) totally unrelated to AChR, was also synthesized and employed as a negative control.

The coupling method for the preparation of mPEG-peptide conjugates is described above and in Atassi and Manshour (1992).

15 mPEG-peptide conjugates is described above and in Atassi and Manshour (1992).

After synthesis of the conjugates and cleavage from the synthesis resin, any residual uncoupled peptide was removed from the conjugate by gel filtration on a column (1.5 x 75 cm) of Sephadex G-75 fine in 0.1 M ammonium bicarbonate. After lyophilization, the mPEG-(α 125-148) conjugate was cyclized and the monomeric species isolated as described (McCormick and Atassi, 1984). A sample of the purified peptide-mPEG conjugate was confirmed to be free of the uncoupled peptide by high performance liquid chromatography (HPLC) on a size exclusion column (Waters protein pack 60, 0.7 X 30 cm) which was eluted with 0.2M ammonium bicarbonate containing 20% acetonitrile at a flow rate of 0.7 ml/min (Fig. 4).

20 removed from the conjugate by gel filtration on a column (1.5 x 75 cm) of Sephadex G-75 fine in 0.1 M ammonium bicarbonate. After lyophilization, the mPEG-(α 125-148) conjugate was cyclized and the monomeric species isolated as described (McCormick and Atassi, 1984). A sample of the purified peptide-mPEG conjugate was confirmed to be free of the uncoupled peptide by high performance liquid chromatography (HPLC) on a size exclusion column (Waters protein pack 60, 0.7 X 30 cm) which was eluted with 0.2M ammonium bicarbonate containing 20% acetonitrile at a flow rate of 0.7 ml/min (Fig. 4).

25 the purified peptide-mPEG conjugate was confirmed to be free of the uncoupled peptide by high performance liquid chromatography (HPLC) on a size exclusion column (Waters protein pack 60, 0.7 X 30 cm) which was eluted with 0.2M ammonium bicarbonate containing 20% acetonitrile at a flow rate of 0.7 ml/min (Fig. 4).

30 flow rate of 0.7 ml/min (Fig. 4).

Tolerization and Immunization

Six weeks old C57/BL6 mice were purchased from Charles River Breeding Laboratories (Wilmington, MA). Preimmune sera were obtained from the mice for use as controls in subsequent antibody binding assays. After

35 Preimmune sera were obtained from the mice for use as controls in subsequent antibody binding assays. After

2-weeks rest, the mice were divided into three groups which received, at eleven, seven and three days before immunization with AChR, an intraperitoneal injection (5 μ g in 25 μ l of PBS) of either the mPEG-(α 125-148) conjugate (Group 1), mPEG-nonsense peptide conjugate (Group 2) or unaltered free peptide α 125-148 (Group 3) (Fig. 5). Then, on day 0, the mice were immunized subcutaneously in one hind footpad and intramuscularly in the same side shoulder with 20 μ g of Torpedo AChR in 100 μ l emulsion containing equal volumes of complete Freund's adjuvant and PBS. Thirty days later, the mice were immunized with a similar dose of the receptor in the opposite footpad and shoulder. On the 37th day, test bleeds were obtained from the mice for determination of the antibody titers. Electrophysiological studies were performed on the 38th and 39th days. Finally, the mice were sacrificed on the 40th day and lymph node cells were obtained for T cell studies.

20 Electrophysiological Studies

To document the electrophysiological evidence of EAMG, amplitudes of serial muscle action potentials were measured by electromyography (EMG) during the repetitive stimulation of the nerve in immunized mice, using the Mystro EMG system (TECA Corporation). A pair of wire electrodes were surgically implanted, encircling the sciatic nerve, two days before EMG. The nerve was stimulated through the implanted electrodes by 3 Hz trains of supramaximal electric current with a duration of 200 microseconds. The corresponding muscle action potentials were recorded with an electrode subcutaneously inserted over the gastrocnemius muscle. A reference electrode was placed at the ankle. Ether inhalation was used during the surgical and recording procedures. The amplitude of the initial evoked potential (P1) was compared to the third, fourth and fifth potentials, and

the potential with the maximum amplitude deviation from the PI on either 3 Hz or 5 Hz stimulation was taken as Ps. The change of the amplitude was calculated as follows:

5

$$\text{Amplitude change \%} = \frac{(Ps - P1)}{P1} \times 100$$

Students' t-test was used to analyze the differences of amplitude changes between the two groups. A typical
10 myasthenic response of a greater than 10% decrement was considered to constitute an electrophysiological evidence of EAMG. The frequency of electrophysiological EAMG was calculated in each group and analyzed by chi-square test.

15 Radioimmunoassay

One mg of the synthetic peptide was dissolved in 50 μ l dimethylformamide and then diluted with PBS to 25 μ g/ml. A solution of Torpedo AChR in PBS was prepared to contain 2.5 μ g/ml. Aliquots (50 μ l/well) of the peptide
20 or AChR solutions were added to a 96-well microtiter plate (Falcon Micro Test III flexible assay plate, Becton Dickinson, Oxcord, CA) and the plates were incubated at room temperature overnight. After washing 3 times with PBS, the plates were blocked with 0.25% bovine serum
25 albumin (BSA) in PBS (50 μ l/well) at 37°C for 90 minutes. The plates were washed again 5 times with PBS and to each well was added 50 μ l of the serum from AChR-immunized mice, pre-diluted with PBS containing 0.10% BSA, and the plates were covered and allowed to stand at room
30 temperature overnight. After 5 washes with PBS, 50 μ l of rabbit IgG antibodies (2.5 μ g/ml) against mouse IgG and IgM (Accurate Chemical Scientific Corporation, Westbury, NY) was added to each well and the plates were incubated at 37°C for 3 hours. The plates were then washed 5 times

with PBS and ^{125}I -labeled protein A (2×10^5 cpm in 50 μl of PBS-0.1% BSA) was added to each well. The plates were incubated for 3 hours at room temperature, after which they were washed and the wells were cut out and counted for bound radioactivity. Pre-immune serum samples, obtained from the mice prior to any experimental treatments, were used as controls to correct for non-specific binding.

10 T Cell Proliferation Assay

Lymph node cells (LNC) were harvested from the AChR-primed mice of each group ten or eleven days after the last AChR immunization. The cells were suspended in RPMI 1640 (Gibco, Grand Island, NY) containing 1% fresh autologous normal mouse serum. The number of viable cells was determined by vital staining with fluorescein diacetate (Rotman and Papermasters, 1966). Viable LNC (5×10^5 cells/well) were co-cultured in triplicate in flat bottom microtiter plates with various concentrations of mitogen, antigen or synthetic peptide in a final volume of 200 μl per well. The antigens used were Torpedo AChR peptides ($\alpha 1-18$ and $\alpha 125-148$, in the dose range 10-40 $\mu\text{g/ml}$), and Torpedo AChR (dose range, 1.5-6.0 $\mu\text{g/ml}$). Lysozyme and ovalbumin (100 $\mu\text{g/ml}$) and synthetic nonsense peptide (ESSGTGIESSGTGI, dose range 10-40 $\mu\text{g/ml}$) were used as negative controls. Concanavalin A (1 $\mu\text{g/ml}$) and lipopolysaccharide (500 $\mu\text{g/ml}$) were used as positive controls to monitor the viability of the cells. After incubation for 3 days at 37°C in a humidified air/ CO_2 (19:1) atmosphere, the cultures were pulsed (18 hr) with 1 $\mu\text{Ci/well}$ [^3H]-thymidine (Research Products International, Mount Prospect, IL) and then harvested on to glass microfiber filters (Whatman, Clinton, NJ) for counting of radioactivity by liquid scintillation.

**Example I: Synthesis of Peptide Conjugates Sequence
ID Nos. 1-7**

After purification, MPEG and PVA peptide conjugates were homogeneous molecular species and were confirmed to be free of the uncoupled peptide by HPLC on a size exclusion column (see Fig. 3, for an example). Furthermore, sequence analysis showed that the N-terminal was free in the uncoupled peptides and was completely blocked in the peptide conjugates. It should be noted that these peptides contained all possible amino acids. Furthermore, the attachment of MPEG or PVA to the N-terminal did not preclude the formation of intramolecular disulfide bonds in appropriate peptides (peptides 5 and 6 in Fig. 1). It is, therefore, clear that this reaction should be universally applicable to coupling MPEG or PVA to any other synthetic peptide.

The present invention allows the preparation of peptide conjugates to mPEG or PVA by using a coupling reaction which ensured that the mPEG was linked to the peptide via its α -amino group on the N-terminal amino acid while the peptide is still attached to resin. This method provided a 1:1, tail-to-head (mPEG or PVA to peptide), monomeric conjugate of high purity. As noted previously, however, chemistries designed to mPEG derivatize the peptides of the invention at the carboxy terminus or at both the amino and carboxy termini are known to those of skill in the art and are expressly included within the scope of the present invention.

30

All the amino acid side chains within the conjugate, except for the N-terminal, remained unaltered and, because they were not attached to mPEG or PVA groups, they were capable of participating in immune recognition and epitope-specific immunoregulatory mechanisms. In contrast to the methods of the invention, mPEG-protein

35

conjugates have been made by coupling mPEG to the protein, usually via ϵ -amino groups of lysine residues (Wei et al, 1981; Nordvall et al, 1986; Holford-Strevens et al, 1987; Jackson et al, 1987). This results in multiple substitutions on the protein surface and in modification of a number of lysine residues. The product would be expected to contain a mixture of molecular species of derivatives. The use of such compounds as tolerogens would potentially give rise to serious problems in reproducibility and efficacy, particularly in the recognition of individual epitopes by the immune system.

The general approach of epitope directed immunosuppression by well-defined tolerogenic peptide conjugates offers useful refined strategies for modulation of antibody responses to immunopathogenic sites on multi-determinant complex protein antigens. Because it provides a means to suppress the production of antibodies against the pathogenic epitopes, it should be applicable to autoantigens, alloantigens and allergens. mPEG itself does not seem to have any harmful or toxic effects in humans. Allergens conjugated to mPEG have already been safely administered to human subjects suffering from asthma (Mosbech et al, 1990) and honeybee venom allergy (Muller et al, 1987). Thus, the invention methods of mPEG or PVA conjugation to peptides should prove important, if not essential, for the employment of these peptide conjugates in specific tolerance to epitopes of protein antigens.

Example II: Specific Peptide Uses**Effect of the mPEG-(α 125-148) Conjugate on the Development of Electrophysiological EAMG**

5 Although some immunized mice showed muscle weakness, quantitative assessment of muscle weakness was difficult and, therefore, muscle action potentials were measured by EMG. Groups 1, 2 and 3 consisted of 25, 27 and 16 mice, respectively. Additional 24 mice received no
10 intraperitoneal injections or immunizations (Group 4). The typical myasthenic decremental response was reversible upon intraperitoneal injection of 250 μ g edrophonium chloride (Fig. 6). The results are summarized in Fig. 7. None of the mice in Group 4 showed
15 a decremental response of the compound action potentials greater than 10%, and their mean amplitude change was +2.8% (i.e. 2.8 increment). Five (20%) of the 25 mice in Group 1 showed a decremental response greater than 10%, while 13 (48%) of the 27 mice of group 2 and 9 (56%) of
20 the 16 mice of Group 3 developed the decremental response. The differences between Group 1 and groups 2 or 3 were statistically significant ($p < 0.05$, chi-square test), but were insignificant between Group 2 and Group 3. The mean amplitude change in Group 1 was -5.4% (i.e.
25 a 5.4% decrement), which was significantly smaller than that in Group 2 (-12.0%; $p < 0.05$) or Group 3 (-15.9%; $p < 0.05$), but greater than in Group 4 (+2.8%; $p < 0.05$).

Effects of Pretreatment with mPEG-(α 125-148) on the Antibody Response

30 The results of antibody binding to AChR and to selected regions of the α chain are summarized in Fig. 8. The antibodies bound to peptide α 125-148 (Fig. 8A) were significantly decreased in the anti-AChR antisera from
35 the group of mice which received the mPEG-(α 125-148) conjugate (Group 1) prior to immunization with Torpedo AChR, whereas mice that had received mPEG-nonsense

peptide (Group 2) or free α 125-148 (Group 3) prior to AChR immunization exhibited no decrease in the antibodies directed against this region (Fig. 8A). Antibodies bound to whole Torpedo AChR (Fig. 8B), to peptide α 45-60 (Fig. 8C) and to peptide α 182-198 (Fig. 8D) were not significantly different among the three groups ($p > 0.1$). To further confirm the epitope specific suppression of the antibody response, serum samples of the mice within each group were pooled and used in serial dilutions for determining the levels of antibodies against the region α 125-148 (Fig. 9). The antiserum mixture from Group 1 [pretreated with mPEG-(α 125-148)] had consistently lower amounts of antibody binding as compared to the antiserum mixture from Group 2 (pretreated with mPEG-Nonsense peptide) and group 3 (pretreated with unaltered free α 125-148) and an additional group of mice without any treatment prior to the immunizations with AChR (Group 5). The antibody levels in Group 3 were consistently greater than the other two controls. Antibodies against peptide α 125-148 were not detectable in Group 4 mice.

Effect of Pretreatment with mPEG-(α 125-148) on the T Cell Proliferative Response

The profiles of T-cell responses in EAMG-positive (pretreated with mPEG-Nonsense peptide) and EAMG-negative mice which had been treated with mPEG(α 125148) were mapped with the synthetic overlapping peptides corresponding to the main extracellular domain (residues 1-210) of the a chain of Torpedo AChR. Lymph node cells from each group of mice were pooled separately based on their electrophysiological status for EAMG. The T cell proliferation profiles did not show meaningful differences among the groups regardless of their electrophysiological status (Fig. 10). The peptide recognition profile by AChR-primed T cells obtained here is in agreement with the profile previously reported for

this mouse strain (Yokoi et al., 1989; Pachner et al., 1989).

Autoantibody-mediated mechanisms which have been demonstrated at the motor end plates in both EAMG and human myasthenia gravis include 1) pharmacological blockade of the acetylcholine binding site; 2) an increased rate of receptor degradation due to cross-linking of adjacent receptors, 3) an activation of the complement-mediated membrane lysis and 4) an alteration of the ion channel properties of the receptor (Ashizawa and Appel 1985). Previous studies with synthetic α 125-148 and with overlapping synthetic peptides which comprised the entire extracellular domain of the α subunit of AChR have illustrated the pharmacological (Lennon et al., 1985) and immunological (Lennon et al., 1985; Mulac-Jericevic et al., 1987) importance of this region. The sequence of the region α 125-148 is highly conserved among species. It binds acetylcholine (McCormick and Atassi, 1984) and contains a universal binding region for long and short α -neurotoxins (Mulac-Jericevic and Atassi, 1987b; Ruan et al., 1990, 1991). Because of its direct involvement in the binding of acetylcholine and since the affinity of the antibodies to the receptor is several orders of magnitude higher than that of acetylcholine, the antibodies are capable of effectively blocking the acetylcholine binding site. Thus, the inventors reasoned that suppression of the antibody response to this region might alleviate the pharmacological blockade of the acetylcholine binding site, leading to the suppression of the development of EAMG.

It has been shown (Abuchowski et al., 1977; Lee and Sehon, 1977, 1978a; King et al., 1977, 1979; Davis et al., 1980; Sehon, 1989) that antibody responses to

proteins can be modulated by protein-mPEG conjugates. It was not known, however, whether the approach may be used to obtain epitope-specific suppression of antibody responses to a preselected region of a protein. The results disclosed here demonstrate that injections of mice with mPEG-(α 125-148) suppressed the development of electrophysiological EAMG induced by subsequent immunizations with whole Torpedo AChR, and this was accompanied by a suppression of autoantibody responses restricted to α 125-148. These findings suggest that suppression of the antibody responses against this region rescued acetylcholine-binding sites on AChR from blockade by such antibodies. Other mechanisms may also play a role, however. Antibodies against the α subunit may be twice as likely to cross-link the adjacent receptors as antibodies against the other subunits, since the AChR is a pentamer consisting of two α subunits and one each of the β , γ and δ subunits. Because of this, and the fact that the region α 125-148 is a major site of recognition by autoantibodies in EAMG, it is very likely that the population of antibodies directed against this region plays an important role in the development of EAMG through accelerated receptor degradation. Likewise, the decrease in this population of autoantibodies may lead to attenuation of the other pathophysiological mechanisms in EAMG.

The suppression of the electrophysiological EAMG was incomplete. Since the suppression of the antibody responses to region α 125-148 was also incomplete, the remaining antibody activities against this region can partially account for the residual disease activity. Antibodies directed against other epitopes were not suppressed by the mPEG-(α 125-148) conjugate and may also produce alterations of the synaptic transmission at the motor end plates through accelerated receptor degradation

or by allosteric effects on the acetylcholine binding site and would thus have pathogenic activities.

Pretreatment with the mPEG-(α 125-148) conjugate, followed by immunization with whole AChR, caused specific decrease of antibody responses directed against region α 125-148, suggesting that the conjugate induces immunosuppression through the regulatory mechanisms involving specific epitope recognition. One of the first steps in immune regulation takes place in the presentation of epitopes to T cells by antigen presenting cells. It has been shown (Holford Strevens et al, 1987), in mice which had developed tolerance to native ovalbumin via intraperitoneal injections of an ovalbumin-mPEG conjugate, that the presentation of mPEG-modified antigen to T helper (Th) cells by peritoneal adherent cells was less efficient than the presentation of native antigen. However, since changes in the T-cell responses to α 125-148 or to other AChR α -chain regions were not detected, it is unlikely that the presentation of mPEG-(α 125-148) to Th cells is impaired. Another mechanism of tolerogenicity caused by the mPEG-(α 125-148) conjugate may involve T suppressor (Ts) cells. A passive transfer of specific Ts cells activated by mPEG-antigen conjugates to syngeneic mice has been shown to cause antigen-specific immunosuppression in the recipient animals, suggesting that induction of antigen-specific Ts cells and release of suppressor lymphokines from these cells may play important roles (Lee et al., 1981; Mokashi et al., 1989; Sehon et al., 1989). Further experiments are needed to elucidate the role, if any, of Ts cells in the immunosuppression caused by the mPEG-peptide conjugate. Immunosuppression of antibody responses mediated by an mPEG-epitope conjugate may also operate at the level of T-B cell collaboration due to impairment of direct contact of the epitope-specific B cells with the

conjugate resulting in central tolerance (Sehon and Lang, 1986). Differences might be expected, however, between the presentation and recognition of mPEG-protein conjugates and mPEG-peptide conjugates because of
5 profound differences in their architecture.

In conclusion, these data suggest that mPEG-modified peptides corresponding to pathogenic autodeterminants of AChR may promise an effective immunospecific treatment
10 for myasthenia gravis in the future. Furthermore, the general approach of epitope directed immunosuppression by well-defined tolerogenic mPEG-peptide conjugates offers useful refined strategies for modulation of antibody responses to immunopathogenic sites on multideterminant
15 complex protein antigens. Because it provides a means to suppress the production of antibodies against the pathogenic epitopes, its application should not be restricted to autoantigens or alloantigens but should also be applicable to allergens. mPEG itself does not
20 seem to have any harmful or toxic effects in humans.

**EXAMPLE III: Clinical Applications of Epitope-Specific
Suppression of Antibody Responses in
Immune Diseases**

25

Methods of Treatment

Allergens conjugated to mPEG have already been safely administered to human subjects suffering from asthma (Mosbech et al., 1990) and honeybee venom allergy
30 (Muller et al., 1987) with therapeutic effects [these references as they pertain to methods of treatment of patients with undesirable immune responses, are specifically incorporated by reference herein]. Sehon (1988) has suggested new clinical applications of mPEG
35 conjugates to arrest the progress of HIV infection to full blown acquired immunodeficiency syndrome (AIDS) in asymptomatic HIV-seropositive individuals. As opposed to

the treatment protocols suggested in these prior art approaches which were limited by the masking of the epitopes by the tolerogenic polymer, the present invention exposes the epitope without masking or altering the conformation of a whole native polypeptide antigen (Sehon 1988).

A method of treatment for an immune disease such as myasthenia gravis, thus, is likely to follow closely these previous drug treatment protocols which used whole antigen. These approaches would be followed except that one would take advantage of the substantial improvement of there being no requirement to take into consideration the masking of the epitopes on the surface of the derivatized whole antigen. Thus, as in Sehon (1988) it was anticipated that the antigen binding capacity of antibodies directed against the allergen would be markedly reduced if not totally impaired as a result of conjugation of the allergen with mPEG. For that reason, in previous studies it was necessary to ensure the efficacy of the antibodies directed to the allergen by including a two-phase approach. In the first stage (immunosuppressive), a series of injections of tolerogenic mPEG conjugates of the antigen would be made for the induction of the immunosuppression as to the various epitopes represented on the whole antigen. In the second (effector) stage, a series of non-conjugated antigens would be injected, either with or without intermittent injections of the tolerogenic derivatives.

In the present invention, since there is no masking of the epitope by the tolerogenic polymer, there is no need to follow the injection of mPeg conjugated peptide epitopes with non-conjugated peptides. This represents a substantial improvement over the prior art approaches. These reagents will then be prepared into a vaccine.

Vaccine Preparation and Use

Immunogenic compositions, believed to be suitable for use as an anti-immune vaccine, may be most readily prepared directly from peptides or peptide analogs of epitopes synthetically prepared and purified in a manner disclosed herein. Preferably the purified material is also extensively dialyzed to remove undesired small molecular weight molecules and/or lyophilization of the thus purified material for more ready formulation into a desired vehicle.

The preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables. Either as liquid solutions or suspensions: solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases,

oral formulations or aerosols. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides: such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%.

The active ingredient will commonly be used as 0.05 to 0.1 percent solution in phosphate buffered saline, admixture with synthetic polymers of sugars (Carbopol) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70° to 101° C for 30 second to 2 minute periods respectively. Aggregation may be accomplished by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed.

30

In many instances, it will be desirable to have multiple administrations of the vaccine, usually not exceeding six vaccinations, more usually not exceeding four vaccinations and preferably one or more, usually at least about three vaccinations. The vaccinations will normally be at from two to twelve week intervals, more

35

usually from three to five week intervals. Periodic boosters at intervals of 1-5 years, usually three years, will be desirable to maintain protective levels of the antibodies. The course of the immunization may be followed by assays for antibodies for the supernatant antigens. The assays may be performed by labeling with conventional labels, such as radionuclides, enzymes, fluorescers, and the like. These techniques are well known and may be found in a wide variety of patents, such as U.S. Patent Nos. 3,791,932; 4,174,384 and 3,949,064, as illustrative of these types of assays.

EXAMPLE IV: Method for screening potential reagents for efficacy in treatment of immune diseases

Immunoassays

It is proposed that the antigenic peptides or analogs of the same peptides of the invention will find utility as immunogens in connection with vaccine development, or as antigens in immunoassays for the detection of anti-peptide antigen-reactive antibodies. Turning first to immunoassays, in their most simple and direct sense, preferred immunoassays of the invention include the various types of enzyme linked immunosorbent assays (ELISAs) known to the art. However, it will be readily appreciated that utility is not limited to such assays, and useful embodiments include RIAs and other non-enzyme linked antibody binding assays or procedures.

In the preferred ELISA assay, peptides incorporating the native antigen sequences (epitopes) are immobilized onto a selected surface, preferably a surface exhibiting a protein affinity such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed material, one will desire to bind or coat a

nonspecific protein such as bovine serum albumin (BSA) or casein onto the well that is known to be antigenically neutral with regard to the test antisera. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.

After binding of antigenic material to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the antisera or clinical or biological extract to be tested in a manner conducive to immune complex (antigen/antibody) formation. Such conditions preferably include diluting the antisera with diluents such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background. The layered antisera is then allowed to incubate for from 2 to 4 hours, at temperatures preferably on the order of 25° to 27° C. Following incubation, the antisera-contacted surface is washed so as to remove non-immunocomplexed material. A preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer.

Following formation of specific immunocomplexes between the test sample and the bound antigen, and subsequent washing, the occurrence and even amount of immunocomplex formation may be determined by subjecting same to a second antibody having specificity for the first. Of course, in that the test sample will typically be of human origin, the second antibody will preferably be an antibody having specificity in general for human Ig. To provide a detecting means, the second antibody will preferably have an associated enzyme that will

generate a color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact and incubate the antisera-bound surface with a urease or peroxidase-conjugated anti-human IgG for a period of time and under conditions which favor the development of immunocomplex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween).

After incubation with the second enzyme-tagged antibody, and subsequent to washing to remove unbound material, the amount of label is quantified by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azido-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H_2O_2 , in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer. It will, of course, be known to those skilled in the art that the chromatogenic protocol outlined above may be substituted by a radiological procedure such as the use of radioactive isotopes of iodine.

Screening Assays

An important aspect of the invention is the use of methods of the invention in screening assays for the identification of substances which may immunosuppress or otherwise modify or alter the undesirable immune response. The use of synthetically produced peptides (epitopes) is of particular benefit because the naturally occurring antigen may only be present in only small quantities and may difficult to purify from other immunogenic substances. Moreover, this allows one a ready source of a wide range of potential epitopes

representing various regions on the surface of a polypeptide antigen.

5 The invention also provides access to human epitopes which may be difficult to produce otherwise if one is limited to collection of the native antigen from human tissues. Even so, by use of the human-derived epitopes in animal models, the sensitivity to various candidate substances can be first screened prior to human trials.
10 The importance of this is quite significant in that it indicates that where one seeks to identify a compound, e.g., that may function to immunosuppress the disease in man, that one should employ human version of a particular epitope of a particular antigen for the screening assay.

15 The screening assays of the invention, in preferred embodiments, conveniently employ the animal model most directly mimicking the disease in humans. The battery of tests shown in Example II above for the disease model for
20 myasthenia gravis are illustrative of the types of tests that can be used, e.g., electrophysiological studies, radioimmunoassays, T-cell proliferations assays, etc.

25 In that most such screening assays in accordance with the invention will be designed to identify agents useful in inhibiting the undesirable immune response, preferred assays will typically employ the native antigen from which the peptides are derived in some aspect. Thus, it is preferred that a source of the native antigen
30 be available.

35 There are believed to be a wide variety of embodiments which can be employed to determine the effect of a candidate substance such as a tolerogenic epitope-specific peptide on the immune disease of the invention, and the invention is not intended to be limited to any

one such method. However, it will generally be desirable to employ a system wherein one can measure the ability of the candidate substance to immunosuppress the disease symptoms in the model.

5

One method employed by the inventors uses a mouse model for the screening of candidate epitopes capable of suppressing the experimental disease symptoms in mice. Similar studies have been accomplished using rat models of human allergy responses to Ra3. As mentioned previously, Grave's disease has well-known animal analogs.

10

In preferred assays, the admixture containing the tolerogenic peptide is injected at various intervals into a test subject and allowed to immunosuppress for a selected amount of time, and the resultant animals are tested for reduction of symptoms of the particular immune disease. Then, one simply measures the amount of each reduction in symptoms of the disease, e.g., versus a control to which no candidate substance has been injected. This measurement can be made at various time points where dosage rate data is desired. From this, one may determine the ability of the candidate substance to alter or modify the immune response of the disease.

20

25

REFERENCES CITED

The following references to the extent that they provide procedural details supplementary to those set forth herein, are specifically incorporated herein by
5 reference.

Abuchowski, A., van Es., T., Palczuk, N.C. and Davis, F.F. (1977) *J. Biol. Chem.* 252, 3578.

10 Anzinger and Mutter, *Polymer Bulletin* 6:595 (1982)

Ashizawa, T. and Appel, S.H. (1985) *Springer Sem Immunopathol.* 8, 177-196.

15 Atassi, H. and Atassi, M.Z. *FEBS Lett.* 188:96 (1985).

Atassi, H. and Atassi, M.Z. *Europ. J. Immunol.* 16:229 (1986).

20 Atassi, M.Z. and Saplin, B.J. (1968) *Biochemistry* 7, 688-698.

Atassi, M.Z., Manshour, T. and Sakata, S. (1991) *Proc. Natl. Acad. Sci. USA* 88, 3613.

25

Atassi, M.Z., Manshour, T. (1992) *J. Prot. Chem.*, in press.

30 Atassi, M.Z., Ruan, J.H., Jinnai, K., Oshima, M. and Ashizawa, T., *Proc. Ntl. Acad. Sci. USA* (1992), submitted

Becker and Bayer, *J. Am. Chem. Soc.* 101:239 (1979)

- Davis, F.F., Abuchowski, A., van Es, T., Palczuk, N.C., Savoca, K., Chen, R.H-L and Pyatuk, P., In "Biochemical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use" (E.P. Goldberg and A. Nakajima, Eds.), pp. 441-452. Academic Press, New York, 1980.
- Froehner, S.C. and Rafto, M.Z. (1979) *Biochemistry* 18, 301-307.
- Holford-Strevens, V., Jackson, C.-J.C., Charlton, J., Akiyama, K.A., Lang, G.M., Carter, B.G. and Sehon, A.H. (1987) *Cellular Immunology* 104, 245-254.
- Jackson, C.-J.C., Charlton, J.L., Kuzminski, K., Lang, G.M. and Sehon, A.H. (1987) *Analytical Biochemistry* 165, 114-127.
- Kaiser, E., Colescott, R.L., Bassinger, C.D. and Look, D.T. (1970) *Anal. Biochem.* 34, 595-598.
- King, T.P., Kochoumian, L. and Lichtenstein, L.M. (1977) *Arch. Biochem. Biophys.* 178, 442.
- King, T.P., Kochoumian, L. and Chiroazzi, N. (1979) *J. Exp. Med.* 149, 424.
- Kita, et al., *Drug Design Delivery* 6:157 (1990)
- Kurisaki, et al. *Europ. J. Immunol.* 16:236 (1986).
- Kyte and Doolittle, *J. Molec. Biol.* 157:105 (1982).
- Laemmli, U. (1970) *Nature (London)* 226, 680-685.
- Lee, W.Y. and Sehon, A.H. (1977) *Nature (London)* 267, 618.

- Lee, W.Y. and Sehon, A.H. (1978a) *Arch. Allergy Appl. Immunol.* **56**, 159.
- Lee, W.Y. and Sehon, A.H. (1978b) *Arch. Allergy Appl. Immunol.* **56**, 193.
- 5
- Lee, W.Y., Sehon, A.H. and Akerblom, E. (1981) *Int. Arch. Allergy Appl. Immunol.* **64**, 100.
- 10
- McCormick, D.J. and Atassi, M.Z. (1984) *Biochem. J.* **224**, 9950-10000.
- Mokashi, S., Holford-Strevens, V., Sterrantino, G. and Jackson, C.J. (1989) *Immunol. Lett.* **23**, 95-102.
- 15
- Mosbech, H., Dirksen, A., Dreborg, S., Frlund, L., Heinig, J.H., Svendsen, U.G., Sborg, M., Taudorf, E. and Weeke, B. (1990) *Allergy* **45**, 142-150.
- 20
- Mulac-Jericevic, B. and Atassi, M.Z. (1987) *J. Prot. Chem.* **6**, 365-373.
- Mulac-Jericevic, B. and Atassi, M.Z. (1987a) *Biochem. J.* **248**, 847-852.
- 25
- Mulac-Jericevic, B. and Atassi, M.Z. (1987b) *J. Prot. Chem.* **6**, 365-373.
- Mulac-Jericevie, B., Kurisaki, J. and Attasi, M.Z. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 3633-3637.
- 30
- Muller, U., Rabson, A.R., Bischof, M., Lomnitzer, R., Dreborg, S. and Lanner, A. (1987) *J. Allergy Clin. Immunol.* **80**, 252-261.
- 35
- Nishimura, et al., *Life Sciences* **33**:1467 (1983)

- Noda, M., Takahashi, H., Tanabe, T., Toyosato, M., Furutani, Y., Hirose, T., Asai, M., Inayama, S., Miyata, T. and Numa, S. (1982) *Nature (London)* 299, 793-797.
- 5 Nordvall, S.L., Uhlin, T., Ohman, S., Bjorkander, J., Malling, H-J., Week, B., Dreborg, S., Lanner, A. and Einarsson, R. (1986) *Allergy* 41, 89-94.
- Pachner, A.P., Kantor, F.S., Mulac-Jericevic, B. and
10 Atassi, M.Z. (1989) *Immunology Letters* 20, 199-204.
- Ruan, K.-H., Spurlino, J., Quiocho, F.A. and Atassi, M.Z. (1990) *Proc. Natl. Acad. Sci. USA* 87, 6156-6160.
- 15 Ruan, K.-H., Stiles, B.G. and Atassi, M.Z. (1991) *Biochem. J.* 274 849-854.
- Sakakibara, S., Shimonishi, Y., Kishida, T., Okada, M. and Sugihara, H. (1967) *Bull. Chem. Soc. Japan* 40, 2164.
- 20 Sartore, et al., *Appl. Biochem. Biotechnol.* 27:55 (1991)
- Sehon, A.H. (1989) *Adv. Exp. Med. Biol.* 251, 341-351.
- 25 Sehon, A.H. and Lang, G.M., In *Mediators of Immune Regulation and Immunotherapy* (S.K. Singhal and T.L. Delovitch, Eds.) pp. 190-203, Elsevier, New York, 1986.
- 30 Sehon, In *Immunobiology of Proteins and Peptides V-Vaccines: Mechanisms, Design, and Applications*, ed. M.Z. Atassi, pp. 341, Plenum Press, New York (1988).
- Ueyama, et al., *Polymer J.* 17:721 (1985)

Wei, S.I., Wei, C.W., Lee, W.Y., Fillion, L.G., Sehon, A.H. and Akerblom, E. (1981) *Int. Arch. Allergy Appl. Immunol.* 64, 84-99.

- 5 Yokoi, T., Mulac-Jericevic, B., Kurisaki, J.T. and Atassi, M.Z. (1987) *Europ. J. Immunol.* 17, 1697-1702.

* * * * *

10

The present invention has been described in terms of particular embodiments found or proposed to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in
15 light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, it will be understood that one may synthesize the peptides of the invention or one
20 may obtain peptide fragments which are either wholly or partially a fragment of a native antigen or a recombinant derivative of such. Additionally, while the amino acid sequence selected for a given peptide will typically occur as such in the native antigen, it will be
25 understood that one may choose to substitute similar hydropathic amino acids and that the peptide may contain non-linear portions (i.e., such a peptide may represent a discontinuous epitope) of a given antigen, alloantigen or allergen. Similarly, one may wish to add amino acid
30 residues to either one or both termini of the epitope proper which amino acid residues are not relevant to the specificity of the epitope but otherwise facilitate its use or ease of purification, for instance. It is also understood that the tolerogenic polymer molecule may be
35 coupled either to the N-terminal α -NH₂ group or to the C-terminal carboxyl group or, in certain cases, to both

termini. All such modifications are intended to be included within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method of producing reagents useful in the treatment of immune diseases, comprising:

5

producing a peptide covalently linked via a first terminal amino acid of said peptide to a resin, said peptide comprising side chain-protected amino acids, said peptide corresponding to an epitope which is suspected of inducing an immune response;

10

derivatizing an opposite second terminal amino acid of said peptide with a tolerogenic polymer;

15

deprotecting the side chain-protected amino acids comprising the peptide;

cleaving the peptide from the resin; and,

20

purifying the peptide.

2. The method of claim 1 wherein said first terminal amino acid is attached to said resin via its carboxyl group.

25

3. The method of claim 1 wherein said second opposite amino acid further provides an α -NH₂ group for derivatization with said tolerogenic polymer.

30

4. The method of claim 1 wherein said peptide is selected from the group of peptides comprising the peptides in Seq ID Nos. 1-7.

35

5. The method of claim 1 wherein said immune disease is selected from the group of diseases consisting of myasthenia gravis, ragweed pollen allergy, and Grave's disease.

6. The method of claim 1 wherein said producing of said peptide further comprises synthesizing said peptide by covalently linking said carboxy-terminal amino acid of said peptide to said resin and polymerizing said side chain-protected amino acids in stepwise fashion to create said peptide.

7. The method of claim 1 wherein said epitope corresponds to a linear sequence of amino acids found in a native polypeptide suspected of causing said immune response in said disease.

8. The method of claim 1 wherein said native polypeptide is selected from the group of native polypeptides comprising a subunit of an acetylcholine receptor, ragweed pollen antigen Ra3, or a subunit of the thyroid-stimulating hormone receptor.

9. The method of claim 1 wherein said immune response is the principal causative agent of symptoms of said disease.

10. The method of claim 1 wherein said tolerogenic polymer is selected from the group of tolerogenic polymers comprising polyethylene glycol, polyethylene

glycol derivatives, polyvinyl alcohol, and polyvinyl alcohol derivatives.

5 11. A method of treating an immune disease, comprising:

producing a tolerogenic polymer-derivatized peptide
as in any of claims 1-8, said peptide
corresponding to an epitope which is suspected
10 of inducing an immune response of said disease;
and,

treating a patient having, or likely to develop,
said immune disease with said peptide prior to
15 onset of a major immune response to a natural
antigen comprising said epitope.

20 12. A reagent useful in the treatment of an immune
disease, comprising a peptide corresponding to an epitope
which is suspected of inducing said immune response, said
peptide derivatized at an N-terminal amino acid of said
peptide with a tolerogenic polymer.

25 13. The reagent of claim 12 wherein said peptide is
selected from the group of peptides comprising the
peptides in Seq ID Nos. 1-7.

30 14. The reagent of claim 12 wherein said peptide
contains functionally equivalent amino acid
substitutions.

35

15. The reagent of claim 12 wherein said epitope corresponds to a linear sequence of amino acids found in a native polypeptide suspected of causing said immune response in said disease.

5

16. The reagent of claim 12 wherein said tolerogenic polymer is selected from the group of tolerogenic polymers comprising polyethylene glycol, polyethylene glycol derivatives, polyvinyl alcohol, and polyvinyl alcohol derivatives.

10

17. A method of producing reagents useful in the treatment of myasthenia gravis comprising:

15

synthesizing a peptide corresponding to the peptide shown in Sequence ID No. 5, said peptide being covalently linked via a carboxy-terminal amino acid of said peptide to a resin, said peptide comprising side chain-protected amino acids, said peptide corresponding to an epitope which is suspected of inducing a myasthenia gravis autoimmune response;

20

25

derivatizing an N-terminal amino acid of said peptide with mPEG;

30

deprotecting the side chain-protected amino acids comprising the peptide;

cleaving the peptide from the resin; and,

purifying the peptide.

35

18. A method of producing reagents useful in the treatment of ragweed allergy, comprising:

5 synthesizing a peptide corresponding to any of the peptides shown in Sequence ID Nos. 1-4, said peptide covalently linked via a carboxy-terminal amino acid of said peptide to a resin, said peptide comprising side chain-protected amino acids, said peptide corresponding to an
10 epitope which is suspected of inducing a ragweed allergy immune response;

derivatizing an N-terminal amino acid of said peptide with mPEG;
15 deprotecting the side chain-protected amino acids comprising the peptide;

cleaving the peptide from the resin; and,
20 purifying the peptide.

19. A method of producing reagents useful in the treatment of Grave's disease, comprising:

synthesizing a peptide covalently linked via a carboxy-terminal amino acid of said peptide to a resin, said peptide comprising side chain-protected amino acids, said peptide
30 corresponding to an epitope on a subunit of a thyroid-stimulating hormone receptor which is suspected of inducing a Grave's disease immune response;

35

derivatizing an N-terminal amino acid of said
peptide with mPEG;

5 deprotecting the side chain-protected amino acids
comprising the peptide;

cleaving the peptide from the resin; and,

10 purifying the peptide.

20. A reagent produced by any of the methods of
claims 17-19.

15

21. A method of treating myasthenia gravis, comprising:

20 producing a tolerogenic polymer-derivatized peptide
as in any of claims 1-10 or 17, said peptide
corresponding to the peptide shown in Sequence
ID No. 5; and,

25 treating a patient having, or likely to develop,
myasthenia gravis with said peptide prior to
onset of a major myasthenia gravis autoimmune
response to an acetylcholine receptor
polypeptide comprising said epitope.

30 22. A method of treating ragweed allergy, comprising:

35 producing a tolerogenic polymer-derivatized peptide
as in any of claims 1-10 and 18, said peptide
corresponding to the peptide shown in Sequence
ID Nos. 1-4; and,

5 treating a patient having, or likely to develop,
 ragweed allergy with said peptide prior to
 onset of a major ragweed allergy immune
 response to ragweed antigen Ra3 comprising said
 epitope.

23. A method of treating Grave's disease, comprising:

10 producing a tolerogenic polymer-derivatized peptide
 as in any of claims 1-10 or 19, said peptide
 corresponding to an epitope which is suspected
 of inducing a Grave's disease immune response;
 and,

15

 treating a patient having, or likely to develop,
 Grave's disease with said peptide prior to
 onset of a major Grave's disease immune
 response to a thyroid-stimulating hormone
20 receptor subunit comprising said epitope.

24. A method of treating myasthenia gravis, comprising:

25 producing, as in claim 17, an mPEG-derivatized
 peptide corresponding to Sequence ID No. 5;
 and,

 injecting said peptide into a patient having or
30 likely to develop myasthenia gravis prior to
 onset of a major autoimmune response to an
 acetylcholine receptor polypeptide comprising
 said epitope.

35

25. A method of treating ragweed allergy, comprising:

producing, as in claim 18, an mPEG-derivatized
peptide corresponding to any of Sequence ID
Nos. 1-4; and,

5

injecting said peptide into a patient having or
likely to develop ragweed allergy prior to
onset of a major immune response to a ragweed
allergen Ra3 polypeptide comprising said
epitope.

10

26. A method of treating Grave's disease, comprising:

15

producing, as in claim 19, an mPEG-derivatized
peptide corresponding to an epitope derived
from the thyroid-stimulating hormone receptor
which is suspected of inducing Grave's disease;
and,

20

injecting said peptide into a patient having or
likely to develop Grave's disease prior to
onset of a major immune response to a thyroid-
stimulating hormone receptor polypeptide
comprising said epitope.

25

27. A method of screening reagents potentially useful in
the treatment of immune diseases, comprising:

30

producing a peptide covalently linked via a first
terminal amino acid of said peptide to a resin,
said peptide comprising side chain-protected
amino acids, said peptide corresponding to an

35

epitope which is suspected of inducing an immune response;

5 derivatizing a second opposite terminal amino acid
 of said peptide with a tolerogenic polymer;

deprotecting the side chain-protected amino acids comprising the peptide;

10 cleaving the peptide from the resin;

purifying the peptide;

15 treating a test subject having, or likely to
 develop, said immune disease or an experimental
 model of said immune disease with said peptide
 prior to onset of an immune response to a
 native allergen comprising said epitope; and

20 evaluating said test subject for alleviation of
 symptoms related to said immune response.

25 28. The method of claim 27 wherein said first terminal
 amino acid is attached to said resin via its carboxyl
 group.

30 29. The method of claim 27 wherein said second opposite
 amino acid further provides an α -NH₂ group for
 derivatization with said tolerogenic polymer.

35 30. The method of claim 24 wherein said peptide is one
 of a battery of peptides whose sequences are derived from
 said native allergen.

31. A method of screening reagents potentially useful in the treatment of myasthenia gravis, comprising:

5 producing a peptide covalently linked via a first
terminal amino acid of said peptide to a resin,
said peptide comprising side chain-protected
amino acids, said peptide corresponding to an
10 epitope which is suspected of inducing an
immune response;

derivatizing a second opposite terminal amino acid
of said peptide with a tolerogenic polymer;

15 deprotecting the side chain-protected amino acids
comprising the peptide;

cleaving the peptide from the resin;

20 purifying the peptide;

treating a test subject having, or likely to
develop, myasthenia gravis or experimental
autoimmune myasthenia gravis with said peptide
25 prior to onset of an immune response to an
acetylcholine receptor polypeptide comprising
said epitope; and

evaluating said test subject for alleviation of
30 symptoms related to said myasthenia gravis.

32. The method of claim 27 wherein said evaluating of
said test subject for alleviation of symptoms further
35 comprises evaluating the test subject using
electrophysiological criteria.


1/9

Peptide	Structure
1.	Gly.Lys.Val.Tyr.Leu.Val.Gly.Gly.Pro.Glu.Leu.Gly.Gly.Trp.Lys
2.	Glu.Val.Trp.Arg.Glu.Glu.Alu.Tyr.His.Ala.Cys.Asp.Ile.Lys.Asp
3.	Pro.Gly.Gly.Pro.Asp.Arg.Phe.Thr.Leu.Leu.Thr.Pro.Gly.Ser.His
4.	Thr.Pro.Gly.Ser.His.Phe.Ile.Cys.Thr.Lys.Asp.Gln.Lys.Phe.Val
5.	$ \begin{array}{c} \text{H}_2\text{N-Lys.Ser.Tyr.Cys.Glu.Ile.Ile.Val.Thr.His.} \\ \\ \text{HO-Ile.Gly.Leu.Lys.Met.Thr.Cys.Asn.Gln.Gln.Asp.Phe.Pro.} \\ \text{Phe} \end{array} $
6.	$ \begin{array}{c} \text{H}_2\text{N-Lys.Ser.Pro.Cys.Ala.Tyr.Lys.Glu} \\ \\ \text{Pro} \\ \text{HO-Cys.Ala.Val.Thr.Thr.Glu} \end{array} $

FIG.1

SUBSTITUTE SHEET

2/9





LEGEND:

P = tolerogenic polymer (mPEG or PVA)
 DCC = dicyclohexylcarbodiimide
 DIPIC = diisopropylcarbodiimide
 X = t-Boc or Fmoc

FIG. 2

SUBSTITUTE SHEET


3/9



SUBSTITUTE SHEET

4/9

FIG. 5






FIG. 6A




FIG. 6B-1










FIG. 6B-2

6/9




7/9

**FIG. 8A****FIG. 8B****FIG. 8C****FIG. 8D**


SUBSTITUTE SHEET

8/9



SUBSTITUTE SHEET

9/9



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/11238

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 07 K 17/08, A 61 K 37/02																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System </td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC⁵ </td> <td style="padding: 5px;">C 07 K 17/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	C 07 K 17/00											
Classification System	Classification Symbols																
IPC ⁵	C 07 K 17/00																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category ⁹</th> <th style="width: 60%; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A2, 0 247 860 (CETUS CORPORATION) 02 December 1987 (02.12.87), claims 1-6. ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 12, 17-20, 27, 31</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">FR, A1, 2 566 780 (INSTITUT PASTEUR ET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 03 January 1986 (03.01.86), claims 1, 2, 9, 10, 11. ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 12, 17-20, 27, 31</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P, A</td> <td style="padding: 5px;">EP, A2, 0 473 084 (SUMITOMO PHARMACEUTICALS COMPANY, LTD.) 04 March 1992 (04.03.92), claims 1-3, 9-11. ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 12, 17-20, 27, 31</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">CHEMICAL ABSTRACTS; vol. 111, no. 15, issued 1989, October 09 (Columbus, Ohio, U.S.A.),</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 12, 17-20, 27, 31</td> </tr> </tbody> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A2, 0 247 860 (CETUS CORPORATION) 02 December 1987 (02.12.87), claims 1-6. ---	1, 12, 17-20, 27, 31	A	FR, A1, 2 566 780 (INSTITUT PASTEUR ET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 03 January 1986 (03.01.86), claims 1, 2, 9, 10, 11. ---	1, 12, 17-20, 27, 31	P, A	EP, A2, 0 473 084 (SUMITOMO PHARMACEUTICALS COMPANY, LTD.) 04 March 1992 (04.03.92), claims 1-3, 9-11. ---	1, 12, 17-20, 27, 31	A	CHEMICAL ABSTRACTS; vol. 111, no. 15, issued 1989, October 09 (Columbus, Ohio, U.S.A.),	1, 12, 17-20, 27, 31
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
A	EP, A2, 0 247 860 (CETUS CORPORATION) 02 December 1987 (02.12.87), claims 1-6. ---	1, 12, 17-20, 27, 31															
A	FR, A1, 2 566 780 (INSTITUT PASTEUR ET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 03 January 1986 (03.01.86), claims 1, 2, 9, 10, 11. ---	1, 12, 17-20, 27, 31															
P, A	EP, A2, 0 473 084 (SUMITOMO PHARMACEUTICALS COMPANY, LTD.) 04 March 1992 (04.03.92), claims 1-3, 9-11. ---	1, 12, 17-20, 27, 31															
A	CHEMICAL ABSTRACTS; vol. 111, no. 15, issued 1989, October 09 (Columbus, Ohio, U.S.A.),	1, 12, 17-20, 27, 31															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">19 April 1993</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">07.05.93</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">BRUS e.h.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">19 April 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">07.05.93</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">BRUS e.h.</div>											
Date of the Actual Completion of the International Search <div style="text-align: center;">19 April 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">07.05.93</div>																
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">BRUS e.h.</div>																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	AJINOMOTO CO. INC. "Modified interlenkin-Z", page 610, column 1, the abstract-no. 132 416k, Jpn. Kokai Tokkyo Koho JP 63 258 896 (88 258 896). -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/11238

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11, 21-26
because they relate to subject matter not required to be searched by this Authority, namely:
(Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods)
Rule 39.1 (iv) PCT
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/US 92/11238 SAE 68676

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentedokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2 247860	02-12-87	AT E 77959	15-07-92
		AU A1 73479/87	03-12-87
		AU B2 595321	29-03-90
		CA A1 1283046	16-04-91
		DE C0 3780218	13-08-92
		DE T2 3780218	17-12-92
		DK A0 2771/87	29-05-87
		DK A 2771/87	01-12-87
		EP A3 247860	11-10-89
		EP B1 247860	08-07-92
		FI A0 872393	28-05-87
		FI A 872393	30-11-87
		JP A2 62289522	16-12-87
		NO A0 872227	27-05-87
		NO A 872227	30-11-87
FR A1 2566780	03-01-86	AT E 44534	15-07-89
		AU A1 45431/85	10-02-86
		AU B2 599004	12-07-90
		CA A1 1268600	01-05-90
		DE C0 3571442	17-08-89
		EP A1 191028	20-08-86
		EP B1 191028	12-07-89
		FR B1 2566780	06-02-87
		WO A1 8600620	30-01-86
EP A2 473084	04-03-92	JP T2 62503169	17-12-87
		CA A2 2050063	01-03-92
		EP A3 473084	29-04-92
		JP A2 4108827	09-04-92
		US A 5183660	02-02-93